Vanderbilt-Ingram Cancer Center

Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology, has been appointed to a leadership role of two newly created cancer research initiatives at Vanderbilt-Ingram Cancer Center. He has been named the founding director of the Center for Cancer Targeted Therapies (CCTT) and director of the Vanderbilt-Ingram Cancer Center Research Network (VICCRN). The CCTT [...]

Harold L. (Hal) Moses, M.D., professor of Medicine and Pathology, and professor and Acting Chair of Cancer Biology, and director emeritus of Vanderbilt-Ingram Cancer Center (VICC), has received the 10th Annual American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research. He received the award April 7 during the AACR Annual Meeting [...]

Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology at Vanderbilt University School of Medicine, has been chosen president-elect for 2013-2014 of the American Association for Cancer Research. Arteaga, who holds the Donna S. Hall Chair in Breast Cancer, also serves as associate director for clinical research and director of the Breast Cancer Research [...]

A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment. The study, led by first author Matthew Resnick, M.D., instructor in Urologic Surgery, Vanderbilt University Medical Center, was [...]

Seventeen members of Vanderbilt University’s faculty have been elected fellows of the American Association for the Advancement of Science (AAAS) this year. This is the largest number of Vanderbilt fellows to be elected in a single year. Vanderbilt University now has 80 AAAS fellows among its current and emeritus faculty. Vanderbilt’s fellows are among 702 [...]

More Tennesseans are expected to die this year from lung cancer than any other form of cancer. Yet, lung cancer research receives far less funding than other forms of the disease. To address this funding disparity, the LUNGevity Foundation will host the second annual Breathe Deep 5-K race/walk event, Saturday, Nov. 17, in Nashville’s Centennial [...]

Caroline Nebhan, right, a fourth-year student in the M.D./Ph.D. training program, explains a cancer research experiment to advocates from the National Lung Cancer Partnership who toured Vanderbilt-Ingram Cancer Center during their recent meeting in Nashville. Nebhan, who works in the research laboratory of William Pao, M.D., Ph.D., is studying the effects of a specific cancer [...]

Angiosarcoma, a rare, aggressive tumor that arises from cells that line blood vessels, has a mortality rate of around 80 percent. Because of their constant contact with the blood stream, these tumors can spread quickly and freely throughout the body. The INK4a/ARF locus on chromosome 9 – a region that encodes tumor suppressor proteins – [...]

Vanderbilt-Ingram Cancer Center’s gastrointestinal Specialized Program of Research Excellence (SPORE) has been awarded its third round of funding by the National Cancer Institute (NCI). “We decided to roll the dice and propose high-risk, high-reward projects,” said Robert Coffey Jr., M.D., Ingram Professor of Cancer Research, professor of Medicine and Cell and Developmental Biology, and director [...]

Overcoming therapeutic resistance that inevitably develops is one of the major challenges in treating lung cancer. Non-small cell lung cancers that harbor mutations in the epidermal growth factor receptor (EGFR) are initially responsive to targeted therapies known as EGFR tyrosine kinase inhibitors (TKIs). However, most patients eventually develop resistance to these therapies. One such targeted [...]